Table 1 –
Patient characteristics at outset of treatment with methotrexate or mycophenolate mofetil as the only immunosuppressive treatment, Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study, 1998–2007
| Variable | MMF | MTX | P-value[a] | |
|---|---|---|---|---|
| Number of Patients | 130 | 222 | ||
| Age (Years) | ||||
| Mean (SD) | 46.49 (16.68) | 41.26 (21.28) | 0.02 | |
| Median (Range) | 48.34 (10–83) | 42.11 (0–90) | ||
| Gender | 0.15 | |||
| Male | 52 (40.0%) | 72 (32.4%) | ||
| Female | 78 (60.0%) | 150 (67.6%) | ||
| Race | 0.46 | |||
| White | 91 (70.0%) | 166 (74.8%) | ||
| Black | 25 (19.2%) | 40 (18.0%) | ||
| Other | 14 (10.8%) | 16 (7.2%) | ||
| Anatomic uveitis diagnosis | 0.0003 | |||
| Anterior uveitis | 18 (13.8%) | 80 (36.0%) | ||
| Intermediate uveitis | 19 (14.6%) | 29 (13.1%) | ||
| Posterior or Panuveitis | 48 (36.9%) | 55 (24.8%) | ||
| Scleritis | 24 (18.5%) | 35 (15.8%) | ||
| Mucous Membrane | 10 (7.7%) | 16 (7.2%) | ||
| Other | 11 (8.5%) | 7 (3.2%) | ||
| Duration of Inflammation (Years) | Median (Range) | 2.05 (0–21) | 1.53 (0–24) | - |
| Bilateral | Yes | 97 (74.6%) | 162 (73.0%) | 0.74 |
| Prior any immunosuppression | Yes | 11 (8.5%) | 16 (7.2%) | 0.67 |
[a]
P-value for group comparisons. Continuous variables analyzed by general linear model. Categorical variables analyzed by χ2 test.
MMF - mycophenolate mofetil
MTX - methotrexate